Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics
- PMID: 34453902
- DOI: 10.1016/j.bcp.2021.114743
Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics
Erratum in
-
Corrigendum to "Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics" [Biochem. Pharmacol. 192 (2021) 114743].Biochem Pharmacol. 2023 Feb;208:115414. doi: 10.1016/j.bcp.2023.115414. Epub 2023 Jan 19. Biochem Pharmacol. 2023. PMID: 36680972 No abstract available.
Abstract
Doxorubicin (Dox) is widely used in chemotherapy regimens for several malignant conditions. Unfortunately, cumulative and irreversible cardiotoxicity of Dox is the most prominent adverse effect which limits its use. Several pharmacological interventions which exert antioxidant properties, including melatonin and metformin, have demonstrated beneficial effects against various cardiac pathological conditions. However, the exact molecular mechanisms underlying their cardioprotective effects are not completely understood. We hypothesized that treatment with either melatonin or metformin provides cardioprotection against Dox-induced cardiotoxicity through mitochondrial protection. Thirty-two male Wistar rats received 6 doses of either 0.9% normal saline solution (0.9% NSS, n = 8) or Dox (3 mg/kg, i.p., n = 24). The Dox-treated rats (n = 8/group) were co-treated with: 1) Vehicle (0.9% NSS), 2) Melatonin (10 mg/kg/day), and 3) Metformin (250 mg/kg/day) for 30 consecutive days via oral gavage. Following the treatment, left ventricular (LV) function, oxidative stress, inflammation, mitochondrial function, dynamics, biogenesis and bioenergetics, mitophagy, autophagy, and apoptosis were determined. Dox induced excessive oxidative stress, inflammation, autophagy, apoptosis, reduced mitochondrial function, dynamics balance, biogenesis, and bioenergetics leading to LV dysfunction. Treatment with either melatonin or metformin exerted equal measures of cardioprotection via reducing oxidative stress, inflammation, autophagy, apoptosis, and improved mitochondrial function, dynamics balance, biogenesis, and bioenergetics in the Dox-treated rats. Melatonin and metformin exerted both anti-cancer and cardioprotective properties, suggesting they have potential roles in concomitant therapy in cancer patients receiving Dox treatment.
Keywords: Doxorubicin-induced cardiotoxicity; Heart; Melatonin; Metformin; Mitochondria.
Copyright © 2021 Elsevier Inc. All rights reserved.
Similar articles
-
AMPK/PGC1α activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis.Free Radic Biol Med. 2018 Dec;129:59-72. doi: 10.1016/j.freeradbiomed.2018.08.032. Epub 2018 Aug 30. Free Radic Biol Med. 2018. PMID: 30172748
-
Promoting mitochondrial fusion in doxorubicin-induced cardiotoxicity: a novel therapeutic target for cardioprotection.Clin Sci (Lond). 2022 Jun 17;136(11):841-860. doi: 10.1042/CS20220074. Clin Sci (Lond). 2022. PMID: 35543245
-
Ivabradine ameliorates doxorubicin-induced cardiotoxicity through improving mitochondrial function and cardiac calcium homeostasis.Biochem Pharmacol. 2025 Jun;236:116881. doi: 10.1016/j.bcp.2025.116881. Epub 2025 Mar 18. Biochem Pharmacol. 2025. PMID: 40112930
-
Cardioprotective strategies against doxorubicin-induced cardiotoxicity: A review from standard therapies to emerging mitochondrial transplantation.Biomed Pharmacother. 2025 Aug;189:118315. doi: 10.1016/j.biopha.2025.118315. Epub 2025 Jul 3. Biomed Pharmacother. 2025. PMID: 40614534 Review.
-
Mechanistic insights into carvedilol's potential protection against doxorubicin-induced cardiotoxicity.Eur J Pharm Sci. 2024 Sep 1;200:106849. doi: 10.1016/j.ejps.2024.106849. Epub 2024 Jul 9. Eur J Pharm Sci. 2024. PMID: 38992452 Review.
Cited by
-
Endothelial-to-Mesenchymal Transition: Potential Target of Doxorubicin-Induced Cardiotoxicity.Am J Cardiovasc Drugs. 2023 May;23(3):231-246. doi: 10.1007/s40256-023-00573-w. Epub 2023 Feb 26. Am J Cardiovasc Drugs. 2023. PMID: 36841924 Review.
-
The Metformin Immunoregulatory Actions in Tumor Suppression and Normal Tissues Protection.Curr Med Chem. 2024;31(33):5370-5396. doi: 10.2174/0929867331666230703143907. Curr Med Chem. 2024. PMID: 37403391 Review.
-
Melatonin in Chemo/Radiation Therapy; Implications for Normal Tissues Sparing and Tumor Suppression: An Updated Review.Curr Med Chem. 2025;32(3):511-538. doi: 10.2174/0109298673262122231011172100. Curr Med Chem. 2025. PMID: 37916636 Review.
-
Exploiting the cardioprotective potential of metformin against cardiotoxic agents.Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 16. doi: 10.1007/s00210-025-04378-3. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40524049 Review.
-
Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity.Int J Mol Sci. 2022 Feb 9;23(3):1912. doi: 10.3390/ijms23031912. Int J Mol Sci. 2022. PMID: 35163838 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources